Ignite Creation Date:
2024-05-06 @ 2:57 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04486651
Status:
UNKNOWN
Last Update Posted:
2021-01-28
First Post:
2020-07-22
Brief Title:
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Sponsor:
Taizhou Hanzhong biomedical co LTD
Organization:
Taizhou Hanzhong biomedical co LTD
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-09-16
Start Date Type:
ACTUAL
Primary Completion Date:
2023-08-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-08-10
Completion Date Type:
ESTIMATED
First Submit Date:
2020-07-22
First Submit QC Date:
July 22 2020
Study First Post Date:
2020-07-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-26
Last Update Post Date:
2021-01-28
Last Update Post Date Type:
ACTUAL